Abstract
Introduction Heart Failure disease management clinics have been historically successful in reducing complications, but little has been done in uninsured settings.
Methods This is a pilot program for uninsured HF patients following a recent hospitalization. Uninsured patients were offered enrollment in the disease management clinic during or immediately following hospitalization for a primary HF diagnosis at our institution during 2021. The program included twice-weekly visits with interprofessional support. Patients were scheduled 16 visits (2 months of follow-up) post-hospitalization. Patients who attended two visits were considered enrolled.
Results Of 59 patients referred, 47(80%) were enrolled. Just four patients (8.5%,95%CI:2.5%,20.5%) were readmitted at 30 days, while four of twelve (33%,95%CI:13.6%,61.2%) were readmitted at 30 days in those who did not enroll. Program participants were readmitted significantly less frequently than national readmission rate estimates (23%,p=0.02).
Conclusion The CHFC3 program is feasible and holds promise for materially reducing 30-day readmissions for HF complications in the uninsured.
Competing Interest Statement
The principal investigator serves as an ad-hoc consultant for GE Healthcare's point-of-care ultrasound line. He received no extramural funding for this work.
Funding Statement
John W Davis is the Principal Investigator and received funding for this project through the University of Texas President's Cabinet Award, a local foundation in Galveston, Texas. The project also received funding from the Sealy and Smith Foundation and the McGovern Academy (William Osler Society). He is also the PI for an NIH TL1 award studying point-of-care ultrasound in heart failure, but these funds were not used towards this project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The program was determined to be IRB-exempt by the University of Texas Medical Branch at Galveston Institutional Review Board. Because the target cohort is a vulnerable population of uninsured adults, we felt it was unethical to pursue a more rigorous design. Because this program was this clinic's only available heart failure care, consent was only obtained insofar as for receiving medical services at the clinic. After the cohort was identified, patient identifiers were removed for data collection and analysis.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
COI Disclosure: Davis (PI, Corresponding Author) is an independent consultant that has provided service to GE Healthcare related to heart failure care with ultrasound. This work has also included cross-consulting with DIA Imaging, Novartis, and PMCardio. He has a UL1 Translational Research Grant (UL1TR001439) studying point-of care ultrasonography in novel settings. Khalife is an investigator on multiple ongoing trials for HF-related outcomes, including one funded by Bayer Pharmaceuticals. In the last five years, he has previously served as co-investigator on trials funded by Novartis, Amgen, Boehringer Ingelheim Pharmaceuticals, and others. Chatila has also served as co-investigator on one trial, previously, funded by Novartis.
The authors declare that they have no other conflict of interest.
Funding: John W Davis is the Principal Investigator and received funding for this project through the University of Texas President’s Cabinet Award, a local foundation in Galveston, Texas. The project also received funding from the Sealy and Smith Foundation and the McGovern Academy (William Osler Society).
Revised to improve emphasis on novelty of implementation (socioeconomically disadvantaged population).
Data Availability
Data is encrypted and stored in REDCap. This can be made available in de-identified fashion with confirmation from the University of Texas Medical Branch IRB.
